Kyverna Therapeutics, Inc. KYTX
We take great care to ensure that the data presented and summarized in this overview for Kyverna Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in KYTX
Top Purchases
Top Sells
About KYTX
Insider Transactions at KYTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 11
2025
|
Karen Marie Walker Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,000
+36.48%
|
-
|
|
Apr 11
2025
|
Ryan Alexander Jones Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+17.66%
|
-
|
|
Jun 06
2024
|
Karen Marie Walker Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,636
+50.0%
|
$38,544
$4.42 P/Share
|
|
May 28
2024
|
Ryan Alexander Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,016
+18.39%
|
$0
$0.73 P/Share
|
|
Feb 12
2024
|
Vida Ventures, LLC |
BUY
Open market or private purchase
|
Indirect |
253,136
+50.0%
|
$5,568,992
$22.0 P/Share
|
|
Feb 12
2024
|
Vida Ventures, LLC |
BUY
Conversion of derivative security
|
Indirect |
4,523,924
+50.0%
|
-
|
|
Feb 12
2024
|
Fred E Cohen |
BUY
Conversion of derivative security
|
Indirect |
4,523,924
+50.0%
|
-
|
|
Feb 12
2024
|
Beth C Seidenberg |
BUY
Conversion of derivative security
|
Indirect |
4,523,924
+50.0%
|
-
|
|
Feb 12
2024
|
Westlake Bio Partners Fund I, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
4,523,924
+50.0%
|
-
|
|
Feb 12
2024
|
Bain Capital Life Sciences Investors, LLC |
BUY
Open market or private purchase
|
Indirect |
450,000
+12.45%
|
$9,900,000
$22.0 P/Share
|
|
Feb 12
2024
|
Bain Capital Life Sciences Investors, LLC |
BUY
Conversion of derivative security
|
Indirect |
2,713,868
+50.0%
|
-
|
|
Feb 12
2024
|
Gilead Sciences Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
910,000
+18.07%
|
$20,020,000
$22.0 P/Share
|
|
Feb 12
2024
|
Gilead Sciences Inc > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,216,119
+50.0%
|
-
|
|
Feb 12
2024
|
Northpond Ventures Iii Gp, LLC |
BUY
Open market or private purchase
|
Indirect |
450,000
+50.0%
|
$9,900,000
$22.0 P/Share
|
|
Feb 12
2024
|
Northpond Ventures Iii Gp, LLC |
BUY
Conversion of derivative security
|
Indirect |
2,805,426
+50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
52.7K
Shares
From
4
Insiders
| Grant, award, or other acquisition | 25K shares |
|---|---|
| Exercise of conversion of derivative security | 27.7K shares |
Sell / Disposition
0
Shares
From
0
Insiders